Carl Byrnes
Stock Analyst at Northland Capital Markets
(1.99)
# 2,668
Out of 4,760 analysts
23
Total ratings
43.75%
Success rate
4.38%
Average return
Main Sectors:
Stocks Rated by Carl Byrnes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLFS BioLife Solutions | Maintains: Outperform | $28 → $31 | $26.62 | +16.45% | 2 | Jan 8, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Outperform | $13 | $5.09 | +145.58% | 1 | Oct 25, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $11 → $13 | $9.62 | +29.94% | 3 | Oct 3, 2024 | |
| MDAI Spectral AI | Initiates: Outperform | $6 | $1.37 | +337.96% | 1 | Aug 12, 2024 | |
| COCH Envoy Medical | Initiates: Outperform | n/a | $1.35 | - | 1 | Dec 21, 2023 | |
| AMRN Amarin Corporation | Maintains: Market Perform | $2 → $1.25 | $0.47 | +165.73% | 1 | Jul 19, 2023 | |
| CDIO Cardio Diagnostics Holdings | Initiates: Outperform | $8 | $0.40 | +1,890.05% | 1 | May 22, 2023 | |
| VTVT vTv Therapeutics | Maintains: Outperform | $60 → $80 | $14.56 | +449.45% | 4 | Aug 17, 2022 | |
| MDXG MiMedx Group | Initiates: Outperform | $23 | $8.12 | +183.25% | 3 | Jul 26, 2021 | |
| ESPR Esperion Therapeutics | Maintains: Market Perform | $30 → $24 | $1.55 | +1,448.39% | 4 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $2,000 | $1.26 | +158,630.16% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.29 | - | 1 | Sep 27, 2017 |
BioLife Solutions
Jan 8, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $26.62
Upside: +16.45%
TriSalus Life Sciences
Oct 25, 2024
Initiates: Outperform
Price Target: $13
Current: $5.09
Upside: +145.58%
BrainsWay
Oct 3, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $9.62
Upside: +29.94%
Spectral AI
Aug 12, 2024
Initiates: Outperform
Price Target: $6
Current: $1.37
Upside: +337.96%
Envoy Medical
Dec 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $1.35
Upside: -
Amarin Corporation
Jul 19, 2023
Maintains: Market Perform
Price Target: $2 → $1.25
Current: $0.47
Upside: +165.73%
Cardio Diagnostics Holdings
May 22, 2023
Initiates: Outperform
Price Target: $8
Current: $0.40
Upside: +1,890.05%
vTv Therapeutics
Aug 17, 2022
Maintains: Outperform
Price Target: $60 → $80
Current: $14.56
Upside: +449.45%
MiMedx Group
Jul 26, 2021
Initiates: Outperform
Price Target: $23
Current: $8.12
Upside: +183.25%
Esperion Therapeutics
May 5, 2021
Maintains: Market Perform
Price Target: $30 → $24
Current: $1.55
Upside: +1,448.39%
Oct 22, 2018
Initiates: Outperform
Price Target: $2,000
Current: $1.26
Upside: +158,630.16%
Sep 27, 2017
Initiates: Outperform
Price Target: n/a
Current: $2.29
Upside: -